Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
Public ClinicalTrials.gov record NCT02843659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from baseline in ESSDAI at Week 12 between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.
Study identification
- NCT ID
- NCT02843659
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2016
- Primary completion
- Jul 23, 2017
- Completion
- Jul 23, 2017
- Last update posted
- Oct 3, 2018
2016 – 2017
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St Joseph Heritage Healthcare | Fullerton | California | 92835 | — |
| Local Institution | Palo Alto | California | 94304 | — |
| Local Institution | Sarasota | Florida | 34239 | — |
| North Georgia Rheumatology Group | Lawrenceville | Georgia | 30096 | — |
| Clinical Pharmacology Study Group | Worcester | Massachusetts | 01605 | — |
| Local Institution | Tupelo | Mississippi | 38801 | — |
| Arthritis And Osteoporosis Associates, Pa | Freehold | New Jersey | 07728 | — |
| New Mexico Clinical Research & Osteoporosis Center | Albuquerque | New Mexico | 87109 | — |
| Local Institution | Mineola | New York | 11501 | — |
| Pmg Research Of Wilmington Llc | Wilmington | North Carolina | 28401 | — |
| Paramount Medical Research & Consulting, Llc | Middleburg Heights | Ohio | 44130 | — |
| Altoona Center For Clinical Research | Duncansville | Pennsylvania | 16635-8406 | — |
| Local Institution | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution | Wexford | Pennsylvania | 15090 | — |
| Acme Research, Llc | Orangeburg | South Carolina | 29118 | — |
| West Tennessee Research Institute | Jackson | Tennessee | 38305 | — |
| Tekton Research Inc | Austin | Texas | 78745 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02843659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2018 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02843659 live on ClinicalTrials.gov.